Synopsis Clinical evidence suggests that extended induction treatment with intravenous risankizumab is effective in increasing clinical response and remission rates. The present study aims to assess the efficacy and safety of risankizumab in patients with moderate to severe Crohn’s disease. This week’s “ MED FACT ” discusses a clinical study from The Lancet Gastroenterology & Hepatology, “ Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study ”. July 2018.
Authors : Brian G Feagan; Julián Panés; Marc Ferrante; et al. Key Takeaways: Risankizumab is superior in achieving clinical remission and clinical response in patients with moderate to severe, treatment-refractory, Crohn’s disease. Objective: To assess the efficacy and safety of risankizumab in patients with moderate to severe Crohn’s disease. Study Type: Double-blind induction trial…
